China Biologic Products, Inc. (the "Company"), through its indirect majority-owned subsidiary Shandong Taibang Biological Products Co. Ltd., is principally engaged in the research, development, production and manufacturing and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. The Company's principal products are human albumin and immunoglobulin products that are used mainly to increase blood volume and for disease prevention and treatment.
Safe Harbor Statement
This press release may contain certain "forward-looking statements"
relating to the business of China Biologic Products, Inc., and its
subsidiary companies. All statements, other than statements of historical
fact included herein are "forward-looking statements," including statements
regarding the ability of the Company to achieve its commercial objectives,
the business strategy, plans and objectives of the Company and its
subsidiaries and any other statements of non-historical information. These
forward-looking statements are often identified by the use of
forward-looking terminology such as "believes," "expects" or similar
expressions, involve known and unknown risks and uncertainties. Although
the Company believes that the expectations reflected in these
forward-looking statements are reasonable, they do involve assumptions,
risks and uncertainties, and these expectations may prove to be incorrect.
Investors should not place undue reliance on these forward-looking
statements, which speak only as of the date of this press release. The
Company's actual results could differ materially from those anticipated in
these forward-looking statements as a result of a variety of factors,
including those discussed in the Company's periodic reports that are filed
with the Securities and Exchange Commission and available on its website
(http://www.sec.gov). All forward-looking statements attrib
|SOURCE China Biologic Products, Inc.|
Copyright©2008 PR Newswire.
All rights reserved